MGMarina Guasch-Jiménez

Marina Guasch-Jiménez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Guasch-Jiménez has a total of 437 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and efficacy of emergent dual antiplatelet therapy after carotid stenting in acute ischemic stroke with tandem lesions

    by Garbiñe Ezcurra-Díaz, Noelia Rodríguez-Villatoro, Pere Cardona Portela, Antonio Doncel-Moriano Cubero, Belen Flores-Pina, Georgina Figueras-Aguirre, Isabel Fernández-Pérez, Tomas Xuclà-Ferrarons, Francisco Purroy-García, Alan Flores, et al.

  • Open Access

    Neurofilament Light Chain and Mutant Huntingtin Across Huntington's Disease Integrated Staging System Stages in Huntington Disease: A Cross‐Sectional Multimodal Analysis

    by Jesús Pérez-Pérez, Gonzalo Olmedo-Saura, Arnau Puig Davi, Rocío Pérez González, Jordi Pegueroles, Andrea Horta-Barba, Anna Vázquez Oliver, Elisa Rivas Asensio, Daniel Alcolea, Juan Fortea, et al.

    Background: The Huntington's Disease Integrated Staging System (HD‐ISS) provides a framework for staging HD but does not incorporate fluid biomarkers. Objective: The aim of this study was to examine neurofilament light chain (NfL) and mutant huntingtin (mHTT) and total tau across HD‐ISS stages and their associations with genetic burden, neuroimaging, and clinical measures. Methods: We performed cross‐sectional analysis of the Barcelona‐Huntington's Disease (BCN‐HD) cohort with external replication in the multicenter HDClarity study. HD gene expansion carriers were classified as HD‐ISS stages 0 to 3. NfL (cerebrospinal fluid [CSF] and plasma), CSF mHTT, total tau, striatal volumes, and Unified Huntington's Disease Rating Scale measures were quantified. Group differences and associations were analyzed using adjusted models. Results: The BCN‐HD cohort included 78 participants (50 HD gene expansion carriers [HDGECs], 28 controls) and HDClarity included 218 participants (166 HDGECs, 52 controls). CSF NfL increased across HD‐ISS stages and discriminated premanifest from manifest individuals, as well as HD‐ISS stage 0 from stage 1. Plasma NfL showed parallel increases and strongly correlated with CSF NfL ( ρ = 0.88, P < 0.001). More than half of HD‐ISS 0 individuals had NfL levels above the age‐adjusted 95th percentile (P95) and shorter predicted time to onset (13 years for CSF and 10 years for plasma). From HD‐ISS 1 onward, NfL levels exceeded P95 in most individuals. Higher NfL concentrations were associated with genetic burden, striatal atrophy, and clinical measures (all P < 0.001). CSF mHTT was detectable from HD‐ISS 0 but showed weaker associations, whereas CSF total tau increased only from HD‐ISS 3. Conclusions: NfL identifies biological activity across the HD‐ISS continuum and shows neuroaxonal injury in a subset of individuals classified as stage 0. These findings suggest that fluid biomarkers may complement current HD‐ISS criteria and support biological stratification in observational studies and clinical trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    White Matter Hyperintensities on Admission CT are Associated with Worse Outcomes But Not Cerebral Edema or Hemorrhagic Transformation After Large Vessel Occlusion Stroke

    by Sophia Dietz, Amrit Avula, Atul Kumar, Marina Guasch-Jimenez, Pol Camps-Renom, Agnieszka M. Slowik, Pawel Wrona, Pwint Lily Thinzar, David Vargas, Nils H. Petersen, et al.

    Introduction: White matter hyperintensities (WMH) are key radiographic biomarkers of cerebral small vessel disease (CSVD) and have been associated with worse outcomes after stroke. Since CSVD may involve blood–brain barrier disruption, we hypothesized that worse outcomes in those with WMH may be mediated through more severe cerebral edema and hemorrhagic transformation (HT). Methods: In this retrospective multicenter cohort study, we studied patients from four multinational stroke cohorts who presented within 12 h of anterior circulation large vessel occlusion (LVO) stroke and received at least one follow-up computed tomography (CT) between 12 and 48 h. WMH were rated on baseline CTs using a Fazekas-derived system, with a subset also assessed with Fazekas grading on magnetic resonance imaging (MRI). Automated image analysis measured cerebrospinal fluid displacement (ΔCSF) and lesional-to-contralateral hemispheric CSF volumes (CSF-ratio) as quantitative edema biomarkers. We analyzed the association between WMH presence and edema severity, hemorrhagic transformation, and poor functional outcome (mRS 3–6), adjusting for key covariates, overall and in the subgroup undergoing thrombectomy and those with successful reperfusion. Results: Of 1290 patients with LVO, 782 were eligible for analysis. Of these, 19% had WMH on CT. Patients with WMH were older, more often female, and had a history of hypertension and higher presenting systolic blood pressure and glucose levels. WMH presence was associated with worse functional outcome, adjusting for age and additional covariates [OR 1.84 (1.06–3.22), p = 0.04] but lower risk of any HT [OR 0.48 (0.25–0.88), p = 0.03]. However, WMH presence by CT or MRI was not associated with edema (ΔCSF, CSF ratio, or midline shift) in the whole population or thrombectomy/reperfusion subgroups. Reperfusion was associated with less edema and improved recovery. Conclusions: Presence of CT-graded WMH was associated with worse outcome after LVO stroke, independent of age and other factors. However, this risk appears not to be mediated through greater risk of HT or cerebral edema formation.

  • Open Access

    Association of circulating endothelial progenitor cell count and functional outcome in patients with acute ischemic stroke due to intracranial large vessel occlusion

    by Ana Aguilera-Simón, Pol Camps-Renom, Marina Guasch-Jiménez, Núria Puig, Elena Jiménez-Xarrié, Rebeca Marín, Marta Soler, Cristina Gallego-Fabrega, Garbiñe Ezcurra-Díaz, Álvaro Lambea-Gil, et al.

    Background: Circulating endothelial progenitor cells (cEPCs) contribute to vascular repair following an ischemic stroke. The aim of the study was to evaluate the association between cEPCs and functional outcomes in patients with acute ischemic stroke (AIS) due to large vessel occlusion (LVO) who received endovascular therapy (EVT). Methods: Prospective study of patients with LVO-AIS who received EVT. Blood samples were obtained within 24±12 hours and on day 7±1 from stroke onset. cEPCs were detected using flow cytometry (CD34+/VEGFR2+/CD133+). The primary endpoint was a favourable functional outcome (modified Rankin Scale 0-2) at three months’ follow-up. Secondary endpoints include baseline to 24 hours/day 7 changes in the National Institutes of Health Stroke Scale (NIHSS) score and collateral circulation (CC) status. Bivariate and multivariable logistic regression analyses were performed. Results: Included were 90 patients (73.2±12.7 years, 41.1% women) in 42 of whom (46.7%) cEPCs were detected at 24 hours. On day 7, cEPCs were detected in 27 (43.6%) of 62 patients for which this information was available. Atrial fibrillation, prior anticoagulant treatment and stroke onset-to-door time <6 hours were associated with lower cEPC counts, and intravenous fibrinolysis therapy was associated with a higher cEPC count on day 7. No association was found between cEPCs and functional outcomes at three months. Patients with the highest cEPC count (Q4) at 24 hours had a lower probability of good CC (46.2% vs 77.3%; p=0.031). Conclusion: cEPC count in patients with LVO-AIS who received EVT was not associated with functional outcomes.

  • Visual versus automated collateral scoring on CT angiography for predicting outcome after endovascular therapy for large-vessel occlusion stroke: a prospective multicentre study

    by Jose Pablo Martinez-Gonzalez, Marina Guasch-Jimenez, Jorge Hernandez-Garcia, Joan Marti Fabregas, Joaquin Ortega-Quintanilla, Francisco Moniche, Isabel Fernández-Pérez, Elena De Celis-Ruiz, Marimar Freijo, Juan F Arenillas, et al.

    Collateral circulation (CC) is a key determinant of tissue viability and clinical outcome in large-vessel occlusion (LVO) stroke. Whether automated collateral scoring on single-phase CT angiography (sCTA) provides prognostic information comparable to traditional visual assessment remains uncertain. This study aimed to compare the predictive performance of visual versus automated collateral evaluation for functional outcome after endovascular therapy (EVT). We conducted a prospective multicentre cohort study including consecutive patients with anterior circulation LVO treated with EVT between 2020 and 2022. Collateral status on baseline sCTA was graded visually (Tan and ASITN/SIR scores) and automatically using Brainomix® software. The primary endpoint was favourable 90-day outcome (modified Rankin Scale [mRS] 0-2). Multivariable logistic regression and ROC analyses compared the discriminative performance of visual and automated collateral assessments. A total of 332 patients (mean age 72.6 ± 12.7 years; 48.5% female) were analysed. Good collateral status was independently associated with favourable outcome for both visual (Tan aOR 2.41, 95% CI 1.09-5.30; p = 0.029) and automated (aOR 2.45, 95% CI 1.11-5.24; p = 0.027) methods. Predictive performance was nearly identical (0.865 for visual and 0.867 for automated assessment; p = 0.777). Good collaterals were also associated with lower mortality and lower risk of symptomatic intracerebral haemorrhage. Automated collateral scoring on baseline sCTA achieves equivalent predictive performance to expert visual assessment for functional outcome after EVT. Their added consistency and reproducibility support the integration of automated methods to standardise collateral evaluation across centres, particularly where immediate expert neuroradiological assessment is not available.

  • Open Access

    Early Diagnostic Performance and Clinical Utility of Neurologist-Performed Focused Cardiac Ultrasound in a Stroke Unit

    by Joan Miquel Fernández-Vidal, Marina Guasch-Jiménez, Garbiñe Ezcurra-Díaz, Álvaro Lambea-Gil, Anna Ramos-Pachón, Alejandro Martinez-Domeño, Luis Prats-Sánchez, Natalia Pérez de la Ossa, Rubén Leta, Juan Fernández-Martínez, et al.

    Background: Cardioembolic sources of embolism (CSOE) account for up to 30% of ischemic strokes, making echocardiography essential for etiologic evaluation. However, access to transthoracic echocardiography (TTE) may delay diagnosis. Focused cardiac ultrasound (FoCUS) has emerged as a rapid point-of-care alternative, but its role within a stroke-tailored cardiac assessment and its potential impact on clinical management and in-hospital workflow remain insufficiently explored. This study aimed to assess the clinical utility of neurologist-performed FoCUS in acute ischemic stroke, including its diagnostic agreement with TTE. Methods: We conducted a prospective, single-center study (January–October 2025) including consecutive patients with acute ischemic stroke admitted to the stroke unit who underwent both FoCUS and TTE during hospitalization. Certified neurologists performed FoCUS following national consensus guidelines. Primary outcome was overall CSOE concordance; secondary outcomes included agreement for high- and low-risk CSOE, agreement for each CSOE category, therapeutic impact, and workflow-related time intervals. Agreement with TTE was assessed using intraclass correlation coefficients and Cohen’s kappa as appropriate. Results: Among 103 included patients (median age 76 years [IQR 62–85], 47% women), FoCUS showed substantial agreement with TTE for overall CSOE (k=0.74) and excellent concordance for high-risk CSOE (k=1.00; 100% sensitivity and specificity). FoCUS was performed significantly earlier than TTE (mean 1.9 vs. 6.0 days; p<0.001). FoCUS identified treatable high-risk CSOE in five previously undetermined strokes. Conclusions: FoCUS demonstrates high diagnostic reliability for clinically significant high-risk CSOE and offers timely cardiac evaluation in acute stroke care. Although not a substitute for TTE, FoCUS represents a valuable complementary tool in the etiologic workup and improves workflow efficiency.

  • Open Access

    Statistical Analysis Plan for the HOPE Trial: a randomized trial on Hemodynamic Optimization of cerebral Perfusion after Endovascular therapy in patients with acute ischemic stroke

    by Pol Camps-Renom, Marina Guasch-Jiménez, Natàlia Pérez de la Ossa, Judit Solà-Roca, Joan Martí-Fàbregas

    Optimal blood pressure (BP) management following endovascular treatment (EVT) for acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion remains unestablished. The randomized HOPE trial (Hemodynamic Optimization of Cerebral Perfusion after Successful Endovascular Therapy in Patients with Acute Ischemic Stroke) ( NCT04892511 ) seeks to determine if a strategy of hemodynamic optimization using different systolic BP targets, tailored to the degree of final recanalization, is superior to standard BP management in improving functional outcomes for these patients. This document outlines the final Statistical Analysis Plan (SAP) for the trial. This plan will be executed after the last follow-up is complete and the dataset has been locked.


  • Effect of Onset-to-Admission Time and Care Bundle Achievement on Functional Outcomes in Patients With ICH

    by Álvaro Lambea-Gil, Joan Marti-Fabregas, Pere Cardona, David Rodriguez-Luna, Mónica Millán, Sergi Amaro, Luis Prats-Sanchez, Yolanda Silva, Laia Seró, Ana Rodriguez-Campello, et al.

    Intracerebral hemorrhage (ICH) remains a leading cause of morbidity and mortality, with limited effective treatments. Early implementation of a care bundle protocol (CBP) within 6 hours of symptom onset has been shown to improve functional outcomes, although its effect beyond this time frame remains unclear. We assessed the impact of onset-to-admission (OTA) time and CBP achievement on functional outcome and mortality in patients with acute spontaneous ICH. We conducted a population-based study of a prospective cohort of consecutive patients diagnosed with acute spontaneous ICH between 2020 and 2022 in Catalonia, Spain. Inclusion criteria were patients aged 18 years or older, OTA time x1h 1.04, 95% CI 1.02-1.06). CBP achievement was associated with a higher probability of favorable outcome at 3 months (aOR 1.66, 95% CI 1.29-2.15). An interaction between OTA time and CBP achievement was observed (p = 0.016), indicating greater CBP benefits for earlier admission. This interaction was evident up to 13.8 hours after symptom onset, with the CBP benefit concentrated in the first 8 hours. Our findings highlight the importance of timely CBP application to improve functional outcome in patients with ICH, even beyond the first 6 hours after symptom onset. While earlier intervention remains ideal, our results support expanding CBP implementation and promoting "Code ICH" initiatives to enhance patient outcomes in stroke care systems. Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT). ClinicalTrials.gov ID: NCT03956485. Registration submission: May 2019. First patient enrolled March 2020. This study provides Class III evidence that in patients with acute ICH, achievement of a standardized CBP is associated with better functional outcomes at 3 months.


  • Emergent Carotid Artery Stenting in Patients With Acute Ischemic Stroke With Tandem Lesions

    by Garbiñe Ezcurra-Díaz, Pere Cardona, Noelia Rodriguez-Villatoro, Antonio Doncel-Moriano Cubero, Belen Flores-Pina, Georgina Laia Figueras-Aguirre, Isabel Fernández-Pérez, Tomas Xuclà-Ferrarons, Francisco Purroy, Alan Flores, et al.

    Management of carotid lesions during endovascular therapy (EVT) in patients with acute ischemic stroke (AIS) due to tandem lesions (TL) remains controversial, and long-term prognosis data are scarce. We evaluated 90-day and 1-year follow-up outcomes of emergent carotid artery stenting (eCAS) vs non-eCAS in these patients. Data from a prospective mandatory population-based registry of Code Stroke in Catalonia (Spain) between 2017 and 2023 were analyzed. Patients with large vessel occlusion and ipsilateral ≥50% atheromatous cervical internal carotid artery (ICA) stenosis undergoing EVT were identified. eCAS and non-eCAS groups were compared. The primary outcome was the shift in the modified Rankin Scale (mRS) score at 90 days and 1 year of follow-up, adjusted using inverse probability of treatment weighting. Stratified analyses in predefined key subgroups according to sex, age, degree of ICA stenosis, Alberta Stroke Program Early CT Score, baseline NIH Stroke Scale, and previous IV thrombolysis were performed. Secondary outcomes included successful recanalization (modified Thrombolysis In Cerebral Infarction ≥2b), 90-day favorable functional outcome (mRS 0-2), hemorrhagic transformation (HT), and 90-day mortality. Among 578 patients included (mean age 70.2 years old, 140 [24.2%] women), 344 patients (59.5%) underwent eCAS. eCAS was associated with a better functional outcome at 90 days (common odds ratio [cOR] for a 1-point less on the mRS score 1.47, 95% CI 1.20-1.82, p < 0.001) and 1 year of follow-up (cOR of 1.47, 95% CI 1.16-1.85, p = 0.001), and with higher successful recanalization rates (OR 4.28, 95% CI 2.61-7.0, p < 0.001), without increasing HT risk or mortality. The benefit of eCAS was consistent in both moderate (50%-69%) and severe (≥70%) ICA stenosis subgroups. Among the eCAS group, patients under dual antiplatelet therapy at 24 hours showed higher rates of favorable functional outcome (54.6% vs 22.9%, p < 0.001). Potential treatment effect differences were observed for women and older patients. In this population-based study of patients with AIS due to TL, eCAS was associated with a better mid-term and long-term functional outcome without safety concerns, even in moderate ICA stenosis. Limitations include the observational design and possible unmeasured confounders. Further studies are needed to explore the mechanisms underlying the differential effects of eCAS in women and older patients. This study provides Class II evidence that in patients with AIS and TL undergoing EVT, eCAS is associated with favorable functional outcome at 90 days compared with EVT alone.


  • Rescue stenting after failed mechanical thrombectomy: The RES-CAT study

    by Roger Collet-Vidiella, Pol Camps-Renom, Ana Núñez-Guillén, Helena Quesada, Federica Rizzo, Noelia Rodriguez-Villatoro, Sergio Amaro, Laura Llull, Daniel Santana, Edgardo Estrada, et al.

    Introduction: The efficacy of intracranial rescue stenting (RS) following failed mechanical thrombectomy (MT) in large-vessel occlusion (LVO) stroke remains uncertain. We aimed to evaluate clinical outcomes of RS in patients with anterior circulation LVO stroke following unsuccessful MT. Patients and methods: We conducted a retrospective analysis using the Stroke Code Registry of Catalonia (January 2016–March 2022), a prospective, population-based registry including patients treated at 10 comprehensive stroke centers. We compared outcomes between patients who received RS and those who did not after failed MT. The primary outcome was the shift in 90-day functional status, assessed by the modified Rankin Scale (mRS), adjusted for confounders using inverse probability of treatment weighting (IPTW). Secondary outcomes included good (mRS ⩽ 2 or 3 if baseline mRS was 3) and excellent (mRS ⩽ 1) outcomes, ischemic recurrences, hemorrhagic transformation, and 90-day mortality. Results: Of 601 patients, 69 underwent RS. RS did not significantly impact the 90-day mRS shift (adjusted common odds ratio [acOR] 1.06, [95% CI 0.85–1.32]; p = 0.613). However, RS was associated with higher rates of good (18.8% vs 11.7%; aOR 1.41, [95% CI 1.00–1.99]; p = 0.048) and excellent outcomes (17.4% vs 5.7%; aOR 2.90, [95% CI 1.89–4.43]; p < 0.001). Symptomatic intracranial hemorrhage (9.4% vs 7.4%; p = 0.507) and 90-day mortality (30.4% vs 39.8%; p = 0.135) were similar between groups. Stroke recurrence (4.2% vs 1.7%; p = 0.247) showed no significant difference at 33-month follow-up. Discussion and conclusion: RS may increase the likelihood of good and excellent outcomes in anterior LVO stroke after failed MT, without increasing long-term risks. Further randomized trials are warranted for comprehensive validation.